GT200500070A - Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos - Google Patents
Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativosInfo
- Publication number
- GT200500070A GT200500070A GT200500070A GT200500070A GT200500070A GT 200500070 A GT200500070 A GT 200500070A GT 200500070 A GT200500070 A GT 200500070A GT 200500070 A GT200500070 A GT 200500070A GT 200500070 A GT200500070 A GT 200500070A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- sulfonamid
- treatment
- neurodegenerative disorders
- invention refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
- C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA I, QUE TIENEN ACTIVIDAD INHIBIDORA DE LA PRODUCCION DE PEPTIDO ALFABETA. LA INVENCION SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR TRASTORNOS Y ENFERMEDADES, POR EJEMPLO, TRASTORNOS NEURODEGENERATIVOS Y/O NEUROLOGICOS, POR EJEMPLO, ENFERMEDAD DE ALZHEIMER, EN UN MAMIFERO, QUE COMPRENDEN COMPUESTOS DE FORMULA I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55866004P | 2004-04-01 | 2004-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200500070A true GT200500070A (es) | 2005-10-31 |
Family
ID=34962303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200500070A GT200500070A (es) | 2004-04-01 | 2005-03-29 | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos |
Country Status (28)
Country | Link |
---|---|
US (2) | US7163942B2 (es) |
EP (1) | EP1747195A1 (es) |
JP (2) | JP2007530660A (es) |
KR (1) | KR20060130705A (es) |
CN (1) | CN1938266A (es) |
AP (1) | AP2006003729A0 (es) |
AR (1) | AR048348A1 (es) |
AU (1) | AU2005227749A1 (es) |
BR (1) | BRPI0509477A (es) |
CA (1) | CA2562114A1 (es) |
CR (1) | CR8669A (es) |
DO (1) | DOP2005000049A (es) |
EA (1) | EA200601607A1 (es) |
EC (1) | ECSP066888A (es) |
GT (1) | GT200500070A (es) |
IL (1) | IL177955A0 (es) |
MA (1) | MA28493B1 (es) |
MX (1) | MXPA06011348A (es) |
MY (1) | MY136718A (es) |
NL (1) | NL1028664C2 (es) |
NO (1) | NO20064989L (es) |
PE (1) | PE20060147A1 (es) |
SV (1) | SV2006002073A (es) |
TN (1) | TNSN06314A1 (es) |
TW (1) | TW200602297A (es) |
UY (1) | UY28825A1 (es) |
WO (1) | WO2005095334A1 (es) |
ZA (1) | ZA200607213B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1465861T1 (sl) | 2001-12-20 | 2009-12-31 | Bristol Myers Squibb Co | Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji |
CN1934091B (zh) * | 2004-03-23 | 2012-02-08 | 辉瑞产品公司 | 治疗神经变性障碍的咪唑化合物 |
JP2009508934A (ja) * | 2005-09-22 | 2009-03-05 | ファイザー・プロダクツ・インク | 神経障害治療のためのイミダゾール化合物 |
MX2009009121A (es) * | 2007-03-05 | 2009-09-03 | Hoffmann La Roche | Aminoamidas como antagonistas de orexina. |
JP2011523633A (ja) * | 2008-05-08 | 2011-08-18 | ブリストル−マイヤーズ スクイブ カンパニー | 2−アリールグリシンアミド誘導体 |
US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
US9359363B2 (en) | 2011-05-20 | 2016-06-07 | Aquinnah Pharmaceuticals, Inc. | Identification of compounds that disperse TDP-43 inclusions |
WO2013026021A2 (en) * | 2011-08-18 | 2013-02-21 | Buck Institute For Research On Aging | Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
CN107722012B (zh) | 2016-08-11 | 2020-05-29 | 斯福瑞(南通)制药有限公司 | 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS484784U (es) * | 1971-06-16 | 1973-01-19 | ||
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5491170A (en) * | 1994-12-19 | 1996-02-13 | Warner-Lambert Company | β-carboxy sulfonamide ACAT inhibitors |
EP0967201A1 (en) | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
ATE438618T1 (de) | 2001-12-14 | 2009-08-15 | Exelixis Inc | Inhibitoren von humanem adam-10 |
SI1465861T1 (sl) | 2001-12-20 | 2009-12-31 | Bristol Myers Squibb Co | Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji |
-
2005
- 2005-03-11 US US11/078,739 patent/US7163942B2/en not_active Expired - Fee Related
- 2005-03-21 WO PCT/IB2005/000796 patent/WO2005095334A1/en active Application Filing
- 2005-03-21 KR KR1020067020447A patent/KR20060130705A/ko not_active Application Discontinuation
- 2005-03-21 BR BRPI0509477-1A patent/BRPI0509477A/pt not_active IP Right Cessation
- 2005-03-21 EP EP05708793A patent/EP1747195A1/en not_active Withdrawn
- 2005-03-21 AU AU2005227749A patent/AU2005227749A1/en not_active Abandoned
- 2005-03-21 MX MXPA06011348A patent/MXPA06011348A/es unknown
- 2005-03-21 JP JP2007505656A patent/JP2007530660A/ja active Pending
- 2005-03-21 EA EA200601607A patent/EA200601607A1/ru unknown
- 2005-03-21 CN CNA2005800106397A patent/CN1938266A/zh active Pending
- 2005-03-21 CA CA002562114A patent/CA2562114A1/en not_active Abandoned
- 2005-03-21 AP AP2006003729A patent/AP2006003729A0/xx unknown
- 2005-03-29 DO DO2005000049A patent/DOP2005000049A/es unknown
- 2005-03-29 PE PE2005000354A patent/PE20060147A1/es not_active Application Discontinuation
- 2005-03-29 UY UY28825A patent/UY28825A1/es not_active Application Discontinuation
- 2005-03-29 GT GT200500070A patent/GT200500070A/es unknown
- 2005-03-30 AR ARP050101227A patent/AR048348A1/es unknown
- 2005-03-30 MY MYPI20051435A patent/MY136718A/en unknown
- 2005-03-31 NL NL1028664A patent/NL1028664C2/nl not_active IP Right Cessation
- 2005-03-31 TW TW094110386A patent/TW200602297A/zh unknown
- 2005-04-01 SV SV2005002073A patent/SV2006002073A/es not_active Application Discontinuation
-
2006
- 2006-08-29 ZA ZA200607213A patent/ZA200607213B/xx unknown
- 2006-09-07 IL IL177955A patent/IL177955A0/en unknown
- 2006-09-27 EC EC2006006888A patent/ECSP066888A/es unknown
- 2006-09-29 MA MA29352A patent/MA28493B1/fr unknown
- 2006-09-29 TN TNP2006000314A patent/TNSN06314A1/fr unknown
- 2006-10-02 CR CR8669A patent/CR8669A/es not_active Application Discontinuation
- 2006-10-06 US US11/539,219 patent/US7345095B2/en not_active Expired - Fee Related
- 2006-10-31 NO NO20064989A patent/NO20064989L/no not_active Application Discontinuation
-
2008
- 2008-02-19 JP JP2008037819A patent/JP2008189673A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20070129349A1 (en) | 2007-06-07 |
NL1028664C2 (nl) | 2006-03-22 |
EP1747195A1 (en) | 2007-01-31 |
NO20064989L (no) | 2007-01-02 |
AR048348A1 (es) | 2006-04-19 |
BRPI0509477A (pt) | 2007-09-11 |
EA200601607A1 (ru) | 2007-02-27 |
MXPA06011348A (es) | 2006-12-15 |
SV2006002073A (es) | 2006-05-09 |
JP2008189673A (ja) | 2008-08-21 |
AP2006003729A0 (en) | 2006-10-31 |
CN1938266A (zh) | 2007-03-28 |
CR8669A (es) | 2006-11-01 |
DOP2005000049A (es) | 2005-12-15 |
CA2562114A1 (en) | 2005-10-13 |
ECSP066888A (es) | 2006-11-24 |
US7345095B2 (en) | 2008-03-18 |
TW200602297A (en) | 2006-01-16 |
AU2005227749A1 (en) | 2005-10-13 |
NL1028664A1 (nl) | 2005-10-05 |
IL177955A0 (en) | 2006-12-31 |
MA28493B1 (fr) | 2007-03-01 |
MY136718A (en) | 2008-11-28 |
US7163942B2 (en) | 2007-01-16 |
TNSN06314A1 (fr) | 2007-12-03 |
JP2007530660A (ja) | 2007-11-01 |
US20050222254A1 (en) | 2005-10-06 |
PE20060147A1 (es) | 2006-03-08 |
KR20060130705A (ko) | 2006-12-19 |
ZA200607213B (en) | 2008-04-30 |
WO2005095334A1 (en) | 2005-10-13 |
UY28825A1 (es) | 2005-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200500070A (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
GT200500060A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
CL2007002288A1 (es) | Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro | |
ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
UY29161A1 (es) | Nuevos heterociclos | |
CR9347A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
BRPI0413245A (pt) | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos | |
UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
UY28484A1 (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
BRPI0409721A (pt) | compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos | |
BRPI0509559A (pt) | compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos | |
GT200600425A (es) | Compuestos de imidazol para el tratamiento de trastornos neurologicos | |
DK1670903T3 (da) | Behandling af neurodegenerative sygdomme | |
BRPI0509582A (pt) | compostos de tiazol-amina e respectivas composições farmacêuticas | |
PA8608601A1 (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
BRPI0509386A (pt) | compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos | |
GT200400227A (es) | Compuestos para el tratamiento de trastornos neurodegenerativos. | |
DOP2006000200A (es) | Compuestos de imidazol para el tratamiento de trastonos neurologicos | |
CU23591B7 (es) | Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos | |
DOP2004000982A (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
DOP2005000205A (es) | Nuevos heterociclos | |
DOP2004000970A (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos |